Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 11/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 11/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 11/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 11/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.37 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.37 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.37 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL568925 | 1.00 | ALDH1A1 (0.53) | ALDH1A1TSHRPDK1PDK2PDK3 | |
| SCHEMBL568924 | 1.00 | ALDH1A1 (0.53) | ALDH1A1TSHRPDK1PDK2PDK3 | |
| SCHEMBL26348105 | 0.85 | THRB (0.46) | ALDH1A1TSHRPDK1PDK2PDK3 | |
| SCHEMBL18562452 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TSHRPDK1PDK2PDK3 | |
| SCHEMBL10472538 | 0.82 | ALDH1A1 (0.64) | ALDH1A1TSHRPDK1PDK2PDK3 | |
| SCHEMBL606619 | 0.82 | ALDH1A1 (0.64) | ALDH1A1TSHRPDK1PDK2PDK3 | |
| SCHEMBL10453248 | 0.82 | ALDH1A1 (0.64) | ALDH1A1TSHRPDK1PDK2PDK3 | |
| SCHEMBL26348102 | 0.81 | THRB (0.54) | ALDH1A1TSHRPDK1PDK2PDK3 | |
| SCHEMBL26348120 | 0.79 | — | — | |
| SCHEMBL5858699 | 0.78 | PDK1 (0.39) | ALDH1A1TSHRPDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013109142-A1 | COMBINED PDK AND MAPK/ERK PATHWAY INHIBITION IN NEOPLASIA | STICHTING HET NEDERLANDS KANKER INSTITUUT (NL) | 2013-07-25 | — | — | WO | claimed |
| US-20110207694-A1 | MAMMALIAN HYPOTHALAMIC NUTRIENT MODULATION OF GLUCOSE METABOLISM | ROSSETTI LUCIANO | 2011-08-25 | — | — | US | claimed |
| EP-0938584-B1 | METHOD OF PREPARING (S) - OR (R) -3,3,3-TRIFLUORO-2-HYDROXY-2- METHYLPROPIONIC ACID | LONZA AG (CH) | 2008-05-28 | — | — | EP | claimed |
| WO-2006119355-A2 | MAMMALIAN HYPOTHALAMIC NUTRIENT MODULATION OF GLUCOSE METABOLISM | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2006-11-09 | — | — | WO | claimed |
| US-6921832-B2 | Optically active fluorine-containing compounds and processes for their production | TOSOH CORPORATION (JP) | 2005-07-26 | — | — | US | claimed |
| US-6773910-B1 | VIA MICROORGANISM (ARTHROBACTER, BACILLUS, KLEBSIELLA, AND PSEUDOMONAS) WHICH UTILIZES PROPIONIC ACID AMIDE COMPOUND AS SOLE NITROGEN SOURCE | LONZA AG (CH) | 2004-08-10 | — | — | US | claimed |
| US-20040147756-A1 | Optically active fluorine-containing compounds and processes for their production | TOSOH CORPORATION (JP) | 2004-07-29 | — | — | US | claimed |
| EP-1422226-A1 | Optically active fluorine-containing compounds and processes for their production | Tosoh Corporation (JP) | 2004-05-26 | — | — | EP | claimed |
| US-20030087402-A1 | Process for the preparation of (S) - or (R) -3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid | BRIEDEN WALTER (CH) | 2003-05-08 | — | — | US | claimed |
| WO-2002004598-A2 | IMPROVEMENT OF CELL CULTURE PERFORMANCE BY INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | IMMUNEX CORPORATION (US) | 2002-01-17 | — | — | WO | claimed |
| EP-4105216-B1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260070910-A1 | NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4699607-A2 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4663189-A2 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-12-17 | — | — | EP | disclosed |
| US-5474999-A | Useful in treatment of urinary incontinence | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-12-12 | — | — | US | disclosed |
| US-5382598-A | Therapeutic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-01-17 | — | — | US | disclosed |
| WO-1994026739-A1 | 1,4-BENZOXAZINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | ZENECA LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
| US-5272163-A | Therapeutic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-21 | — | — | US | disclosed |
| EP-0524781-A1 | Therapeutic amides | ZENECA LIMITED (GB) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147756-A1 | Optically active fluorine-containing compounds and processes for their production | CYP2C19, CYP2F1, CYP2B6 | ALDH1A1 898/4885TSHR 986/4885PDK1 2335/4885 |
| US-20260070910-A1 | NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF | PC, CS, IDH2 | ALDH1A1 1306/4885TSHR 4004/4885PDK1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.